OMERACT超声痛风结构病变在降尿酸治疗中的敏感性评估
本研究纳入50例经显微镜验证的痛风患者,在启动或增加降尿酸治疗后第3和6个月重复超声检查28个关节和26条肌腱。结果显示双轨征和痛风石总分在3个月和6个月均显著下降,而聚集和侵蚀变化有限,提示超声结构病变评分可用于监测降尿酸治疗中的尿酸盐沉积。
要点
- 双轨征和痛风石总分在降尿酸治疗3个月和6个月均显著下降。
- 聚集总分仅从3个月到6个月显著下降,侵蚀总分几乎无变化。
- 第一跖趾关节是最常见受累部位,也是评分变化最明显的区域。
核心结论
- 按二分类评分的OMERACT超声痛风结构病变可用于监测降尿酸治疗期间的尿酸盐沉积。
- 双轨征和痛风石在治疗仅3个月后即显示出敏感性变化。
研究设计与样本
- 对50例经显微镜验证的痛风患者(48例男性,平均年龄68.9岁,范围30-88岁)在启动或增加降尿酸治疗时及第3、6个月进行超声检查。
- 超声评估28个关节和26条肌腱,对OMERACT结构痛风病变(双轨征、痛风石、聚集、侵蚀)进行二分类评分,并计算患者和病变层面的总分。
主要发现
- 双轨征总分从0个月3.16降至3个月2.33和6个月1.34(所有p<0.002)。
- 痛风石总分从0个月2.68降至3个月2.43和6个月1.83(所有p<0.002)。
- 聚集总分仅从3个月6.02降至6个月5.02(p=0.002),侵蚀总分几乎不变。
- 所有四种结构病变最常见于第一跖趾关节(双侧>1个病变),第二至第四跖趾关节和膝关节也常见,尤其是双轨征。
临床怎么用
- 超声评估OMERACT结构痛风病变(尤其是双轨征和痛风石)可作为降尿酸治疗早期(3个月)监测尿酸盐沉积的工具。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the sensitivity to change of ultrasound structural gout lesions, as defined by the Outcome Measures in Rheumatology (OMERACT) ultrasound group, in patients with gout during urate-lowering therapy (ULT). METHODS: Ultrasound (28 joints, 26 tendons) was performed in patients with microscopically verified gout initiating or increasing ULT and repeated after 3 and 6 months. Joints and tendons were evaluated by ultrasound for presence of the OMERACT structural gout lesions-double contour sign (DC), tophus, aggregates and erosion-scored binarily. A sum score was calculated at patient and lesion level. Changes at 3 and 6 months in patient sum scores and lesion scores at different locations were evaluated. RESULTS: 50 patients (48 men), mean age 68.9 (range, 30-88) years, were included. Ultrasound showed a statistically significant decrease in DC and tophus sum scores from 0 months (3.16 and 2.68, respectively) to 3 months (2.33 and 2.43) and 6 months (1.34 and 1.83) (all p<0.002). The aggregate sum score only decreased significantly from 3 to 6 months (6.02 to 5.02, p=0.002), whereas erosion sum score remained almost unchanged. All four structural lesions were most commonly found in metatarsophalangeal (MTP) 1 joints (>1 lesions bilaterally), and furthermore MTP2-4 and knee joints were common sites especially for DC. Likewise, these regions were the locations with most pronounced changes in scores. CONCLUSION: Ultrasound assessment of the OMERACT structural gout lesions scored binarily seems to be a useful tool for monitoring urate depositions during ULT. Particularly DC and tophus showed sensitivity to change after only 3 months of treatment.
引用
- Christiansen SN, Østergaard M, Slot O, et al. Assessing the sensitivity to change of the OMERACT ultrasound structural gout lesions during urate-lowering therapy. RMD Open. 2020. PMID: 32396518. doi:10.1136/rmdopen-2019-001144
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。